Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.66 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.60 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14518616 | 1.00 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL11124876 | 0.90 | NFE2L2 (0.54) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL11124874 | 0.90 | NFE2L2 (0.54) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL118591 | 0.90 | NFE2L2 (0.79) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL21798669 | 0.84 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL615385 | 0.84 | NFE2L2 (0.77) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL1546324 | 0.83 | NFE2L2 (0.59) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL1045609 | 0.82 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL1045608 | 0.82 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL5205155 | 0.82 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583708-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2025-07-16 | — | — | EP | claimed |
| CN-120091758-A | Arthropod control composition | 弗门尼舍有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-20250113823-A1 | Arthropod Control Compositions | FIRMENICH SA (CH) | 2025-04-10 | — | — | US | claimed |
| EP-4444095-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2024-10-16 | — | — | EP | claimed |
| CN-118591291-A | Arthropod control composition | 弗门尼舍有限公司 | 2024-09-03 | — | — | CN | claimed |
| WO-2024084006-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2024-04-25 | — | — | WO | claimed |
| WO-2023139053-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2023-07-27 | — | — | WO | claimed |
| EP-4583708-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2025-07-16 | — | — | EP | disclosed |
| CN-120091758-A | Arthropod control composition | 弗门尼舍有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250113823-A1 | Arthropod Control Compositions | FIRMENICH SA (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4444095-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2024-10-16 | — | — | EP | disclosed |
| CN-118591291-A | Arthropod control composition | 弗门尼舍有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024084006-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023139053-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2023-07-27 | — | — | WO | disclosed |
| CN-1301964-C | Inhibitors of alpha 4-mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2007-02-28 | — | — | CN | disclosed |
| US-6299785-B1 | Electrode formation process | JSR CORPORATION (JP) | 2001-10-09 | — | — | US | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250113823-A1 | Arthropod Control Compositions | AGO2, EXOSC9, C5 | NFE2L2 4634/4885CYP1A1 2185/4885CYP1A2 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.